NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

BioInvent International AB (publ) (ST: BINV)

 
BINV Technical Analysis
5
As on 26th Feb 2026 BINV STOCK Price closed @ 23.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 32.34 & Strong Sell for SHORT-TERM with Stoploss of 33.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BINVSTOCK Price

Open 26.05 Change Price %
High 26.05 1 Day -3.00 -11.41
Low 22.75 1 Week -1.90 -7.54
Close 23.30 1 Month -6.65 -22.20
Volume 370261 1 Year -20.90 -47.29
52 Week High 44.20 | 52 Week Low 23.30
 
ST Sweden Most Active Stocks
QUIA 0.00 %
LIPI 0.22 -4.35%
IMMNOV 0.25 38.89%
ACTI 0.05 0.00%
SBB-B 4.06 4.37%
SOLT 0.11 0.00%
EPIS-B 0.04 0.00%
LUNE 21.97 6.65%
NIBE-B 36.41 3.73%
POLY 0.04 0.00%
 
ST Sweden Top Gainers Stocks
KOPY 0.10 150.00%
IMMNOV 0.25 38.89%
SPIFF 0.04 33.33%
FLEXQ 15.50 32.48%
RO 0.28 27.27%
RO 0.28 27.27%
SOZAP 0.25 25.00%
ECC-B 0.58 18.37%
WBGR-B 4.94 15.69%
NILS 3.46 15.33%
 
ST Sweden Top Losers Stocks
SECI 0.01 -50.00%
SECI 0.01 -50.00%
PCAT 3.35 -44.17%
ZICC 0.25 -34.21%
AUR 0.82 -31.67%
AUR 0.82 -31.67%
ALLR 1.55 -26.54%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
 
 
BINV
Daily Charts
BINV
Intraday Charts
Whats New @
Bazaartrend
BINV
Free Analysis
 
BINV Important Levels Intraday
RESISTANCE29.66
RESISTANCE27.62
RESISTANCE26.36
RESISTANCE25.10
SUPPORT21.50
SUPPORT20.24
SUPPORT18.98
SUPPORT16.94
 
BINV Forecast February 2026
4th UP Forecast42.09
3rd UP Forecast36.06
2nd UP Forecast32.34
1st UP Forecast28.61
1st DOWN Forecast17.99
2nd DOWN Forecast14.26
3rd DOWN Forecast10.54
4th DOWN Forecast4.51
 
BINV Weekly Forecast
4th UP Forecast32.26
3rd UP Forecast29.39
2nd UP Forecast27.61
1st UP Forecast25.83
1st DOWN Forecast20.77
2nd DOWN Forecast18.99
3rd DOWN Forecast17.21
4th DOWN Forecast14.34
 
BINV Forecast2026
4th UP Forecast67.91
3rd UP Forecast53.6
2nd UP Forecast44.76
1st UP Forecast35.92
1st DOWN Forecast10.68
2nd DOWN Forecast1.84
3rd DOWN Forecast-7
4th DOWN Forecast-21.31
 
 
BINV Other Details
Segment EQ
Market Capital 2163430656.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BINV Address
BINV
 
BINV Latest News
 
Your Comments and Response on BioInvent International AB (publ)
 
BINV Business Profile
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden. Address: The Gamma Building, Lund, Sweden, 223 70
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service